Compare MIRA & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRA | BDRX |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 1.6M |
| IPO Year | 2023 | 2015 |
| Metric | MIRA | BDRX |
|---|---|---|
| Price | $0.73 | $0.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 172.8K | ★ 7.1M |
| Earning Date | 11-12-2026 | 09-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.60 |
| 52 Week High | $2.45 | $11.88 |
| Indicator | MIRA | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 35.79 |
| Support Level | $0.72 | $0.61 |
| Resistance Level | $1.02 | $1.52 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 56.48 | 1.18 |
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.